Journal Scans
A Phase II Study of Intraperitoneal Paclitaxel Plus Cisplatin and Intravenous Paclitaxel Plus Bevacizumab As Adjuvant Treatment of Optimal Stage II/III Epithelial Ovarian Cancer
Cisplatin, Paclitaxel, and Bevacizumab in Ovarian Cancer
JA Konner, DM Grabon, SR Gerst, A Iasonos, H Thaler, SD Pezzulli, PJ Sabbatini, KM Bell-McGuinn, WP Tew, ML Hensley, DR Spriggs, CA Aghajanian
20111007
2011 Nov 7
J Clin Oncol
A Phase II Study of Intraperitoneal Paclitaxel Plus Cisplatin and Intravenous Paclitaxel Plus Bevacizumab As Adjuvant Treatment of Optimal Stage II/III Epithelial Ovarian Cancer
J Clin Oncol. 2011 Nov 7;[Epub Ahead of Print], JA Konner, DM Grabon, SR Gerst, A Iasonos, H Thaler, SD Pezzulli, PJ Sabbatini, KM Bell-McGuinn, WP Tew, ML Hensley, DR Spriggs, CA Aghajanian
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Ovarian cancer is the fifth most common cause of cancer-related death in women. Standard adjuvant chemotherapy for optimally debulked ovarian cancer consists of intraperitoneal (IP) cisplatin and intravenous (IV) or IP paclitaxel. In several randomized clinical studies, IP chemotherapy regimens demonstrated a survival advantage superior to IV-only regimens. Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, has been shown to prolong progression-free survival (PFS) when...
